Clinical trials: Diabetic Kidney Disease
Kidney Diseases, Kidney Failure, Chronic
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
A central goal of this data repository is to collect data from a large population of subjects with a variety of renal disease states.
- Conditions
- Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis
- Trial name
- RENAL AID (NCT01802034)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- The Rogosin Institute
Contrast-induced Nephropathy
Role of Amlodipine in Reduction of CIN
The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit
- Trial name
- NCT07291375
- Testing
- Calcium channel blocker, Hydration
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Minia University
Chronic Kidney Disease
Therapeutic Drug Use for CKD Patients
Chronic kidney disease (CKD), characterized as renal dysfunction, is recognized as a major public health problem with high morbidity and mortality worldwide.
- Trial name
- NCT05818995
- Testing
- angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Qianfoshan Hospital
Type 1 Diabetes Mellitus With Diabetic Nephropathy
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children
About 30 to 40% of patients suffering from type I diabetes are at risk of developing a diabetic nephropathy (DN) leading more or less rapidly to an end-stage renal disease.
- Trial name
- peeDIAB2 (NCT02164279)
- Testing
- Urinary sample collection
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Toulouse
Chronic Renal Failure
Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy
Diabetes kidney disease is a leading cause for end stage renal disease in the western world. To date no treatment that can reverse renal damage exists.
- Trial name
- NCT03376282
- Testing
- Hyperbaric Oxygen oxygen therapy (HBOT)
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Assaf-Harofeh Medical Center
Diabetic Nephropathy, Diabetes Mellitus
Soy Protein in Early Diabetic Nephropathy
Diabetic nephropathy is a frequent cause of end-stage renal disease. Reduction of dietary protein has been used to slow down renal disease progression, but patients are often unwilling to make these dietary changes.
- Trial name
- NCT00067678
- Testing
- soy protein
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Diabetes Mellitus, Type I, Diabetic Nephropathy
Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease
The primary aim is to evaluate the anti proteinuric effect of increasing doses of the ACE inhibitor, lisinopril: 20, 40 and 60 mg daily in type 1 diabetic patients with hypertension and diabetic nephropathy.
- Trial name
- NCT00118976
- Testing
- Lisinopril
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetic Kidney Disease, Extracellular Matrix Alteration
The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Diabetic kidney disease (DKD) is the leading cause for renal replacement therapy in developed country. DKD is also the primary cause of ESKD among middle-aged and elderly people in China.
- Trial name
- NCT06049550
- Testing
- no intervention
- Volunteers
- 250 people
- Sponsor
- RenJi Hospital
Diabetic Kidney Disease, Chronic Kidney Disease
Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
The purpose of this study is to evaluate the long-term safety, efficacy, and durability in participants with chronic kidney disease (CKD) who received up to four REACT injections, delivered percutaneously into either the same or…
- Trial name
- NCT06790498
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Prokidney
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy
The research team will perform a comparative-effectiveness sequential, multiple assignment, randomized trial in painful diabetic neuropathy (PDN) patients for 8 total months, divided into two 4-month stages.
- Trial name
- MCPAIN (NCT07795593)
- Testing
- Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
- Where
- 23 sites in United States
- Volunteers
- 600 people
- Sponsor
- University of Michigan
Diabetic Nephropathy
Colchicine for Diabetic Nephropathy
Patients with diabetic nephropathy and proteinuria, despite maximal anti- hypertensive and anti-glucose treatment, will receive colchicine for six months, 2 mg a day, during which their 24 hour urine protein and renal function…
- Trial name
- NCT01005121
- Testing
- colchicine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Prof.Avi Livneh
Diabetic Nephropathy, Proteinuria
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
The study is done to find out whether the combined use of the nutritional supplements N-acetylcysteine and Siliphos (milk thistle extract) corrects the shedding of urine protein and oxidative damage (damage to cells and organs…
- Conditions
- Diabetic Nephropathy, Proteinuria, Oxidative Stress
- Trial name
- CGDN (NCT01265563)
- Testing
- N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes
Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes
The aim of this study is to detail the (mechanisms underlying the) actions of the DPP-4 inhibitor linagliptin on the renal system in patients with type 2 diabetes mellitus.
- Trial name
- RENALIS (NCT02106104)
- Testing
- Linagliptin 5 mg QD (N=24), Glimepiride 1 mg QD (N=24)
- Where
- Netherlands
- Volunteers
- 48 people
- Sponsor
- Amsterdam UMC, location VUmc
End Stage Renal Disease, Continuous Ambulatory Peritoneal Dialysis
Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR
Phase IV post-marketing study to evaluate the effect of Extraneal on the HOMA index in non-diabetic CAPD patients over the long-dwell exchange.
- Trial name
- ECOS (NCT01093547)
- Testing
- Blood samples, Measure of peritoneal ultrafiltrates
- Where
- Colombia
- Sponsor
- Vantive Health LLC
Diabetic Nephropathies
Comprehensive Management of Diabetic Patients With Renal Impairment : Impact on Blood Pressure and Glycemic Control
Diabetes is the leading cause of end-stage renal disease in developed countries. Hypertension and metabolic control are known to affect the progression of renal deficiency and patient's outcome.
- Trial name
- NCT00306436
- Testing
- comprehensive management
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Diabetic Nephropathy Type 2
Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
At present, the early diagnosis ability of diabetic nephropathy (DKD) is relatively poor, leading to some missed diagnosis of early disease patients.
- Trial name
- NCT04962399
- Testing
- Enzyme linked immunosorbent assay
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Zheng Guo
Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus
Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.
The global prevalence of diabetes is increasing substantially. Around 40 % of patients with type 2 diabetes develop chronic kidney disease.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Trial name
- FineCaRe (NCT07026539)
- Testing
- Finerenone (BAY 94-8862)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Chronic Kidney Disease, Diabetic Nephropathy
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Prospective, randomized, double-blind, placebo controlled, 12-week, multicenter study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets compared to placebo in…
- Trial name
- NCT01424319
- Testing
- Atrasentan low dose group, Atrasentan high dose group
- Where
- 18 sites in Japan
- Volunteers
- 58 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Nephropathy
Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which…
- Trial name
- NCT00240019
- Testing
- Addition of furosemide 20 mg oral bid to baseline regimen
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Diabetic Nephropathy, Chronic Kidney Disease
Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
Diabetic nephropathy has become the single most frequent cause of end-stage renal disease. On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these…
- Conditions
- Diabetic Nephropathy, Chronic Kidney Disease, Diabetes Type 2
- Trial name
- NCT00556465
- Testing
- N-acetylcysteine
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences